Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0034065 (pulmonary embolism)
 14,979 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Oral anticoagulants are generally accepted as secondary prophylaxis in patients with thromboembolic disease. Long term oral anticoagulant treatment of 24 survivors of clinically acute massive pulmonary embolism (AMPE) was assessed. There were following indications for such a treatment: recurrent PE/DVT in history and/or continuous risk factors. In the group of survivors of AMPE with continuing risk factors or the recurrence of that disaster the long-term oral anticoagulant therapy is effective, relatively safe and therefore justified.
Pneumonol Alergol Pol 1994
PMID:[Secondary prevention by using oral anticoagulants in patients with clinically acute massive pulmonary embolism]. 806 40

The rate of both: false-positive and false-negative diagnoses of pulmonary embolism (PE) is high. To determine the accuracy of the ante-mortem diagnosis of PE we reviewed 78 autopsies and compared the clinical and pathological diagnoses in that group. In 64 cases PE was diagnosed clinically: in 43 it was confirmed by autopsy (67%). In 21 cases (33%) the clinical diagnoses were false-positive. There were 57 pathological diagnoses altogether: in 14 cases (25%) the clinical diagnoses were false-negative. Among falsely diagnosed patients, the diagnoses of myocardial infarction, pneumonia and malignancy were most frequent. We tried to find some distinctive features separating the cases in the subgroups. Among them venous diseases were more frequent in PE than in falsely diagnosed patients.
Pneumonol Alergol Pol 1994
PMID:[Evaluation of agreement between clinical and pathomorphologic diagnosis of pulmonary embolism]. 806 41

Among 121 patients with pulmonary embolism (PE) five (4%) developed pericardial syndrome, connected with PE. Other known causes of pericarditis were ruled out. In 3 cases corticosteroids were administered with anticoagulants and/or fibrinolytic agents without complications. We believe that the clinician considering in similar situations the risk-benefit ratio of anticoagulant or/and fibrinolytic therapy should certainly use corticosteroids and not abstain from the use of anticoagulants and/or fibrinolytic agents in presence of pericardial syndrome after PE. In cases with huge pericardial effusion catheter should be inserted into pericardial space, because of high probability of cardiac tamponade.
Pneumonol Alergol Pol 1994
PMID:[Pericarditis during the course of pulmonary embolism]. 806 42

Two cases of MOFS (multi-organ-failure-syndrome) are presented. Pulmonary embolism was an initial presentation in one case, acute pneumonia in the other. In both cases intensive supportive treatment including mechanical ventilation was instituted because of acute respiratory failure. Sequential dysfunction and/or failure of other organs were observed. Both patients died despite 3 and 7 weeks of intensive treatment, respectively. In both cases MOFS was confirmed by autopsy.
Pneumonol Alergol Pol 1994
PMID:[Multi-organ failure syndrome. Clinical picture: report of 2 cases]. 806 47

Pulmonary embolism remains an important cause of mortality despite recent advances in medical therapy. The inferior vena cava filter has been devised for treatment of pulmonary embolism. The Gunter inferior vena cava filter was inserted percutaneously in 6 patients with recurrent pulmonary embolism despite anticoagulation therapy. No complications were observed during this procedure. Two patients died after filter placement (one after six weeks one after 1.5 year) because of right heart failure observed before procedure. The other four patients showed no signs of pulmonary embolism during four years follow-up. We conclude that percutaneous insertion of the Gunter filter is a safe and effective technique for prevention of recurrent pulmonary embolism.
Pol Arch Med Wewn 1994 Jan
PMID:[Long term observations of patients after percutaneous inferior vena cava filter placement for recurrent pulmonary embolism]. 819 Jun 56

In the case of 53 years old woman LGM filter was inserted over renal veins. Indications for those procedures were: vena cava thrombosis in distal part of vena cava what not allowed to place filter below renal veins, malignancy, planned surgery, proximal deep vein thrombosis and past history of pulmonary embolism. Indications for suprarenal placement of vena cava filters and results of such as procedure were discussed.
Pneumonol Alergol Pol 1995
PMID:[Implantation of a LGM suprarenal vena cava filter--case report]. 852 May 62

Case of recurrent, clinically acute massive pulmonary embolism treated with rtPA (administered 0.6 mg/kg, during 10 minutes simultaneously with heparin) is presented. Minimal clinical improvement was observed after mentioned procedure. Good clinical response was achieved after LGM filter insertion into vena cava inferior. Clinical course was complicated by Dressler-like syndrome successfully treated with steroids. Problems of massive pulmonary embolism, vena cava filter prophylaxis and pericardial complication of pulmonary embolism are discussed.
Pneumonol Alergol Pol 1995
PMID:[Prophylactic use of the LGM filter in a patient with a recurrent clinically acute massive pulmonary embolism complicated by pericarditis--case report]. 852 May 63

In 53 patients with recent (< 6 hrs) acute myocardial infarction a study was undertaken to evaluate the safety of conjunctive therapy with streptokinase (1.5 mln U), aspirin (150 mg) and low molecular weight heparin (Fraxiparine). Patients were treated with Fraxiparine 250 U anti-Xa IC/kg/24 hrs iv for 2 days (with bolus 12.5 U anti-Xa IC/kg), and 125 U anti-Xa IC/kg twice a day sc for 5 subsequent days. Clinical course in one-year observation was compared regarding the time the therapy was initiated. In the group undergoing therapy 3-6 hrs after the infarct had occurred 4 (7.5%) patients died (2 during hospitalization, 2 after discharge). In 31 patients treated within 3 hrs of the myocardial infarction there were fewer cases of recurrent myocardial infarction, unstable angina or congestive heart failure necessitating rehospitalization their (9.1%) than in 22 patients included in the treatment regimen between 3 rd and 6th h of the infarction (27.3%). Earlier thrombolysis was also connected with higher left ventricular ejection fraction (55 +/- 8% vs 49 +/- 10%) and more frequent peak CK-MB values 12 hrs after thrombolysis (81% and 68% of patients respectively). Neither symptomatic deep vein thrombosis nor pulmonary embolism was detected. The left ventricular thrombosis was diagnosed by echocardiography in 4 of 20 patients (20%) with the first anterior myocardial infarction. There was neither bleeding requiring blood transfusion nor cerebrovascular stroke. The treatment with Fraxiparine did not induce the prolongation of APTT values. Conjunctive thrombolytic therapy with low molecular weight heparin was safe and followed by a favorable outcome of the acute myocardial infarction, especially if instituted within the first 3 hrs after the onset of infarction.
Pol Arch Med Wewn 1996 Jan
PMID:[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up]. 867 95

We present a case report of primary hepatocellular carcinoma with tumor thrombus extending into the right atrium complicated by pulmonary embolism. A 49-year-old man was admitted to our hospital for searching a cause of thrombus in the right atrium. The patient complained of shortness of breath and oedema of the lower extremities. He had a history of hepatitis B. Abdominal sonography and computed tomography revealed a tumor of the liver. A needle biopsy confirmed the diagnosis of hepatocellular carcinoma. Magnetic resonance showed a tumor thrombus also in the inferior vena cava. The diagnosis of pulmonary embolism was confirmed by pulmonary perfusion scintigraphy. This case stresses that clinicians should include hepatocellular carcinoma among the possible causes of intracardiac thrombus and pulmonary embolism.
Pol Arch Med Wewn 1996 Mar
PMID:[A case of primary hepatocellular carcinoma with tumor thrombus in the right atrium and massive pulmonary embolism]. 875 55

The incidence and clinical significance of pulmonary embolism (PE) in pulmonary malignancy were analysed among 111 autopsy cases including: 65 primary and 24 metastatic lung cancer, 8 hematological malignancies and 14-malignant pleural mesothelioma. In 34 (31%) cases PE was found, in 4 (12%) patients cancer tissue emboli was documented. In nonsmall cell lung cancer the frequency of PE was 40%, compared to 24% in small cell, 25% in metastatic lung cancer and 14% in mesothelioma. Deep venous thrombosis of lower extremities was the source of thrombotic material in 35% cases. In remaining cases the sources of thrombotic material were different (caval vein inferior, superior, and their main branches, right heart cavities, pulmonary artery). In 8 patients with PE the acute form of DIC was observed. In 15 (44%) patients the clinical ante mortem diagnosis of PE was done. In 26% of all analysed cases PE was the direct cause of death. We concluded that PE is a frequent and dangerous complication of lung neoplasms. Clinical diagnosis can be extremely difficult.
Pneumonol Alergol Pol 1996
PMID:[Pulmonary embolism in malignancy of the lung: a retrospective clinical evaluation and pathomorphologic personal material]. 898 39


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>